2026年葛兰素史克历年年报/社会责任报告/ESG报告合集（共42套打包）

1、GSK delivers strong Q3 performance and upgrades 2025 guidanceSpecialty Medicines,Vaccines and General Medicines drive sales,profit and earnings growthTotal Q3 2025 sales 8.5 billion+7%AER;+8%CERSpeci。

2、Investor Relations Q3 2025 results 1 Confidential Conference call and webcast for investors and analystsConference call and webcast for investors and analysts Wednesday,Wednesday,29 October29 October。

3、Pipeline assets and clinical trials appendixQ3 2025Infectious disease2ContentsInnovation:Pipeline growthClinical trialsRespiratory,Immunology and Inflammation(RI&I)OncologyHIVInfectious DiseasesI。

4、Q3 2025 ResultsQ3 2025 ResultsConference call and webcast for investors and analystsConference call and webcast for investors and analysts29 October 202529 October 20252AgendaAgendaQ3 2025 strong per。

5、GSK delivers continued strong performanceStrong Specialty Medicines performance drives sales and core operating profit growthTotal Q2 2025 sales 8.0 billion+1%AER;+6%CERSpecialty Medicines sales 3.3 。

6、 Investor Relations Q2 2025 results presentation Page 1 of 27 Wednesday,Wednesday,3 30 0 JulyJuly 2022025 5 at 1at 12 2:00:00 BSTBST Introduction|Constantin Fest Slide 1|Q2 2025 Results Slide 2|Agend。

7、Pipeline assets and clinical trials appendixQ2 2025Infectious disease2ContentsInnovation:Pipeline growthClinical trialsRespiratory,Immunology and Inflammation(RI&I)OncologyHIVInfectious DiseasesI。

8、Q2 2025 ResultsQ2 2025 ResultsConference call and webcast for investors and analystsConference call and webcast for investors and analysts30 Jul 202530 Jul 20251AgendaAgendaQ2 2025 performance moment。

9、1Inside this reportStrategic report1Ahead Together2Business model42024 performance and keyperformance indicators6Chairs statement8CEOs statement10Our external environment12Research and development32C。

10、As filed with the Securities and Exchange Commission on March 3,2025UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)O。

11、GSK makes strong start to 2025 with growth in sales,profits and earningsSpecialty Medicines growth drives Q1 performanceTotal Q1 sales 7.5 billion+2%AER;+4%CERSpecialty Medicines sales 2.9 billion(+1。

12、Investor Relations Q1 2025 results presentation 1 Introduction|Constantin Fest Slide 1|Q1 2025 Results Slide 2|Agenda Ladies and gentlemen,a very warm welcome to this GSK Q1 2025 results call.My name。

13、Pipeline assets and clinical trials appendixQ1 2025Infectious disease2ContentsInnovation:Pipeline growthClinical trialsRespiratory,Immunology and Inflammation(RI&I)OncologyHIVInfectious DiseasesI。

14、Q1 2025 ResultsConference call and webcast for investors and analystsConference call and webcast for investors and analysts30 April 202530 April 20252AgendaAgendaQ1 2025 performance on trackQ1 2025 p。

15、 At GSK,we unite science,technology and talent toget ahead of disease together.We aim to positively impact the health of 2.5 billion peopleby the end of the decade,as a successful,growing companywher。

16、Annual Report 2022GSK Annual Report 2022Strategic reportAhead Together 012022 performance and key performance indicators 02Chairs statement 04CEOs statement 06Business model 08Our culture and people 。

17、强劲的增长前景卓越的品类领先品牌组合，具有吸引人的全球布局和竞争能力，在一个不断增长的1,500亿以上的行业中表现出色的战略，这比以往任何时候都更重要，中期4-6%的年度有机销售增长，可持续的适度利润率扩张和高现金转换具有投资能力和交付股东回报的诱人增长前景我们制定了我们的战略，在2022年2月的消费者医疗保健资本市场日上，我们将展示其能力和增长雄心。。

18、Annual Report 2020ContentsStrategic reportOur business model 01Chairmans statement 03CEOs statement 04Financial performance 06Our long-term priorities 09Our culture 10Key performance indicators 11Ind。

19、Annual Report 2019ContentsStrategic reportOur business model 01Chairmans statement 03CEOs statement 04Financial performance 06Our long-term priorities 09Our culture 10Key performance indicators 11Ind。

20、Annual Report 2018ContentsGSK Annual Report 2018Strategic reportGSK at a glance 01Chairmans statement 02CEOs statement 03Financial performance 04Our long-term priorities 07Key performance indicators 。

21、Annual Report2017Image HIV virusGSK Annual Report 2017Cover image30 years after developing the first HIV medicine,our research into treatment and prevention of HIV continues.We remain at the forefron。

22、Annual Report 20162016 saw good sales momentum across Pharmaceuticals,Vaccines and Consumer Healthcare and further pipeline progressCautionary statement regarding forward-looking statementsThe Groups。

23、Annual Report 20152015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals,Vaccines and Consumer Healthcare businessesB GSK Annual Report 2015Strategic 。

24、Annual Report 2014“I am proud to work on our respiratory portfolio and know how important these medicines are to the lives of patients.”Julie,GSK respiratory packaging operator,Ware,UKGSK Annual Repo。

25、Annual Report 2013“Being active and having a positive outlook on life is what keeps me going every day.”Please go to page 4 for moreMore at Cautionary statement regarding forward-looking statementsTh。

26、Annual Report 2012Do more,feel better,live longerbGSK Annual Report 2012 A child being seen by a doctor working for Brazils unified health system,which provides 95%of scheduled vaccinations in the co。

27、2011Do more,feel better,live longerAnnual Report for shareholdersOur Board 78Our Corporate Executive Team 80Governance and policy 84Share capital and control 95Committee reports 97US law and regulati。

28、GlaxoSmithKline Annual Report 2010Do more,feel better,live longerGSK Annual Report 2010Business review2010 Performance overview 08Research and development 10Pipeline summary 12Products,competition an。

29、 GSK is changingAnnual Report 2009Do more,feel better,live longerHead Office and Registered OfficeGlaxoSmithKline plc980 Great West RoadBrentford,Middlesex TW8 9GSUnited KingdomTel:+44(0)20 8047 5000。

30、Annual Report 2008Grow Deliver SimplifyDo more,feel better,live longerFind out more about GSK WebsiteGlaxoSmithKlines website gives additional information on the Group.Information made available on t。

31、Answering the Questions that mAtterAnnual Report 2007WebsiteGlaxoSmithKlines website gives additional information on the Group.Information made available on the website does not constitute part of th。

32、A humanraceAnnual Report 2006Do more,feel better,live longerFinancial summary*CER%growth is on an IFRS basis for 2006 and 2005 and a UK GAAP,business performance basis for 2004 and earlier.In order t。

33、Annual Report 2005Do more,feel better,live longerhuman beingDo more,feel better,live longerAbout us Our products Your health ResponsibilityIn the community Research&Development Investors Media ce。

34、Do more,feel better,live longerNew challengesNew thinkingAnnual Report 2004GlaxoSmithKline plc is an English public limited company.It shares are listed on the London Stock Exchange and theNew York S。

35、1 March 2025Basis of Reporting Social&Governance 2024Table of ContentsBasis of Reporting 2Governance of Changes to Published Data 2Data Management 2Data Collection and Documentation 2High Level D。

36、1Annual review 2003GlaxoSmithKline Annual Report Do more,feel better,live longer every day Improving performance ANNUAL REPORT 2003 GlaxoSmithKline 01 MissionOur global quest is to improve the qualit。

37、1 March 2025GSK report against the following metrics for all sites under operational control as defined in our organisational boundary approach.Our reporting period covers 1 January to 31 December.GS。

38、The Impact of MedicinesAnnual Report 2002Do more,feel better,live GlaxoSmithKline plc is an English public limited company.Its shares are listed on the London Stock Exchange and the New York Stock Ex。

39、1 GSK Responsible Business Performance Report 2024March 2025Responsible Business Performance Report 20242 GSK Responsible Business Performance Report 2024March 2025Our purpose is to unite science,tec。

40、Connecting.Annual Report 2001GlaxoSmithKline plc is an English public limited company.Its shares are listed on the London Stock Exchange and the NewYork Stock Exchange.GlaxoSmithKline plc acquired Gl。

41、ESG Performance Report 2021March 2022In this report:Our Trust priority 1Progress in 2021 Science and technology 2Affordability and availability 4Modern employer 7Operating responsibly 11Environment 1。

42、GlaxoSmithKline01GlaxoSmithKline plcAnnual Report for the year ended 31st December 2000ContentsReport of the Directors02 Financial summary03 Joint statement by the Chairman and the Chief Executive Of。